Skip to main content

ERRATUM article

Front. Pharmacol., 21 October 2021
Sec. Pharmacology of Ion Channels and Channelopathies
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.788046

Erratum: Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies

This article is an erratum on:

  1. Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies

    1. Read original article
Frontiers Production Office Frontiers Production Office*
  • Frontiers Media SA, Lausanne, Switzerland

An Erratum on
Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies

by Wanichawan, P., Skogestad, J., Lunde, M., Støle, T. P., Stensland, M., Nyman, T. A., Sjaastad, I., Sejersted, O. M., Aronsen, J. M. and Carlson, C. R. (2021). Front. Pharmacol. 12:638646. doi:10.3389/fphar.2021.638646

Due to a production error, the incorrect Supplementary Material files were published. The Supplementary Material files have been corrected.

The publisher apologizes for this mistake. The original article has been updated.

Keywords: PLM, NCX1, disruptor peptide, NKA, cardiac, brain, peptide arrays, peptidomimetics

Citation: Frontiers Production Office (2021) Erratum: Design of a Proteolytically Stable Sodium-Calcium Exchanger 1 Activator Peptide for In Vivo Studies. Front. Pharmacol. 12:788046. doi: 10.3389/fphar.2021.788046

Received: 01 October 2021; Accepted: 01 October 2021;
Published: 21 October 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Frontiers Production Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Production Office, pharmacology.production.office@frontiersin.org

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.